CYR-064 Phase 2 FLAVOR Trial Results to be Featured at the 72nd Annual Meeting of the American Rhinologic Society

Oral presentation to highlight Phase 2 data evaluating CYR-064 for persistent post-viral loss of smell

DELRAY BEACH, Fla., July 29, 2026 /PRNewswire/ — Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced that an abstract detailing results from the Company’s Phase 2 FLAVOR clinical trial evaluating CYR-064 for persistent post-viral loss of smell (hyposmia) was accepted for an oral presentation at the 72^nd Annual Meeting of the ARS being held October 15-17, 2026, in Los Angeles, California. The FLAVOR Trial abstract has been given the first presentation slot of the ARS General Session on October 16^th and will lead the “Oral Presentations: Top 5 Clinical Science” track.

Titled, “FLAVOR phase 2 RCT: Theophylline nasal spray for persistent post-viral hyposmia,” the presentation will be delivered by Masayoshi Takashima, MD, FARS, Principal Investigator of the FLAVOR trial, and will highlight data from the FLAVOR Phase 2 randomized, double-blind, placebo-controlled trial evaluating CYR-064 in patients suffering from persistent post-viral loss of smell across 14 clinical sites in the U.S.